Many batches of Johnson & Johnson vaccines are banned in the US "problem factory" and the other two batches are approved for export

　　The US Food and Drug Administration notified on the 11th that multiple batches of Johnson & Johnson's new crown vaccine produced by a US factory were "not suitable for use", but at the same time it approved the other two batches of Johnson & Johnson vaccines produced by this factory for domestic vaccination or export.

　　The FDA said in a statement that other batches of vaccines produced by this factory are being evaluated.

The statement did not mention the specific quantities of the above-mentioned batches of vaccines.

　　The Johnson & Johnson new crown vaccine was developed by Johnson Pharmaceuticals Co., Ltd., a subsidiary of Johnson & Johnson, and requires only one dose.

So far, all Johnson & Johnson vaccines distributed and vaccinated in the United States are produced in the Netherlands.

　　In the United States, Emerging Biotech is a vaccine manufacturer of Johnson & Johnson, whose factory is located in Baltimore, Maryland.

This factory had many problems before, including mixing the raw materials of Johnson & Johnson vaccine and AstraZeneca vaccine, substandard sanitation, and irregular production process. In April, it was ordered to suspend production by the Food and Drug Administration.

As many as 15 million doses of Johnson & Johnson vaccine were scrapped due to mixing up of raw materials.

　　The FDA said in its latest statement that it has not yet decided whether to approve the resumption of production at the Baltimore plant.

　　The US "New York Times" and other media reported on the 11th that the FDA required Johnson & Johnson to "must discard" about 60 million doses of the problematic vaccine, and the two batches of vaccines approved for use amounted to about 10 million doses.

　　According to multiple media reports, in accordance with the requirements of the China Food and Drug Administration, even if the Johnson & Johnson vaccine is approved for use, it will be accompanied by warning signs, stating that "regulatory agencies cannot guarantee that emerging biotech companies follow a good production process."

　　Reuters reported on the 11th that Johnson & Johnson plans to export vaccines produced at its Baltimore plant overseas.

　　The European Medicines Agency said in a statement on the 11th that Johnson & Johnson delivered a batch of vaccines to Europe before and after the Baltimore plant had "contamination" of raw materials.

As a precaution, the European Medicines Agency does not recommend the use of this batch of vaccines in Europe.

Reuters reported that this batch of vaccines numbered in the millions.

　　The Canadian drug regulatory agency said later on the 11th that it will not distribute the approximately 300,000 doses of the new crown vaccine previously delivered by Johnson & Johnson, which are all produced at the Baltimore plant.

(Zheng Haoning) (Xinhua News Agency special feature)